首页 - 信息快讯

科学家描绘肝癌药物基因组学 “蓝图”

发布时间:2019-08-14   信息来源:图书馆

中国科学院分子细胞科学卓越创新中心惠利健研究组、中国科学院上海营养与健康研究所李亦学研究组、第二军医大学附属东方肝胆外科医院张海斌研究组以及南京大学医学院附属鼓楼医院施晓雷等取得一项新进展。他们的研究公布了目前最大的肝癌细胞模型库 LIMORE 及最详细的药物基因组学。这一成果发表在 8 月 12 日出版的《癌细胞》上。

为了表征肝癌中药物基因组相互作用的情况,研究人员开发了一种方案,以大约 50% 的成功率建立人肝癌细胞模型,并用 81 个细胞模型生成肝癌模型库(LIMORE)。LIMORE 能够代表原发癌的基因组和转录组异质性。对 LIMORE 药物基因组学领域的研究发现了新的基因—药物关联,包括对肝癌普遍改变的合成致死率。此外,这也为选择索拉非尼响应患者提供了预测性生物标志候选物。LIMORE 为促进肝癌的药物发现提供了丰富的资源。

据了解,肝癌具有高度异质性、预后差以及药物反应差等特征。更好地理解基因改变和药物反应之间的关系将有助于肝癌的精确治疗。


 2019 Aug 12;36(2):179-193.e11. doi: 10.1016/j.ccell.2019.07.001. Epub 2019 Aug 1.

A Pharmacogenomic Landscape in Human Liver Cancers.

Qiu Z1Li H2Zhang Z1Zhu Z3He S4Wang X5Wang P6Qin J7Zhuang L3Wang W8Xie F8Gu Y8Zou K2Li C2Li C1Wang C1Cen J1Chen X1Shu Y1Zhang Z1Sun L1Min L1Fu Y9Huang X6Lv H5Zhou H8Ji Y10Zhang Z11Meng Z3Shi X12Zhang H13Li Y14Hui L15.

Abstract

Liver cancers are highly heterogeneous with poor prognosis and drug response. A better understanding between genetic alterations and drug responses would facilitate precision treatment for liver cancers. To characterize the landscape of pharmacogenomic interactions in liver cancers, we developed a protocol to establish human liver cancer cell models at a success rate of around 50% and generated the Liver Cancer Model Repository (LIMORE) with 81 cell models. LIMORE represented genomic and transcriptomic heterogeneity of primary cancers. Interrogation of the pharmacogenomic landscape of LIMORE discovered unexplored gene-drug associations, including synthetic lethalities to prevalent alterations in liver cancers. Moreover, predictive biomarker candidates were suggested for the selection of sorafenib-responding patients. LIMORE provides a rich resource facilitating drug discovery in liver cancers.

KEYWORDS:

liver cancer; patient-derived cancer models; pharmacogenomics; sorafenib




Copyright 2018年 天津市肿瘤医院 图书馆 版权所有

今日访问量: 59 总访问量: 10669

鄂ICP备19029798号-1 公安备案号:42011102002773号